Form 4: BioCardia Director Granted 12,000 Stock Options

BioCardia, Inc. Director Simon H. Stertzer was granted 12,000 stock options with an exercise price of $1.37, vesting one year from the grant date.

Summary

• Simon H. Stertzer, a Director of BioCardia, Inc. (BCDA), was granted 12,000 stock options.
• The options have an exercise price of $1.37 per share.
• The grant date for these options was December 8, 2025.
• The options will vest 100% on the one-year anniversary of the grant date, specifically December 8, 2026, provided Mr. Stertzer continues as a service provider.
• The expiration date for these options is December 8, 2035.
• Following this transaction, Mr. Stertzer beneficially owns 15,573 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally viewed as a neutral to slightly positive event, as it aligns the director's interests with long-term shareholder value. It is a routine compensation disclosure rather than a performance indicator.

Positives

• The grant of stock options to a director aligns their financial interests with those of the company's shareholders, encouraging long-term value creation.
• The transaction indicates continued commitment and service from a key director to BioCardia, Inc.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the vesting schedule of the granted options.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of long-term incentive compensation to align leadership interests with shareholder value creation. This is a standard disclosure for insider transactions.

Comparison to Industry Standards

• Stock option grants are a standard component of executive and director compensation packages across various industries, including biotechnology. The specific terms, such as exercise price relative to current market price and vesting schedule, are typical for such grants.
• Without specific details on BioCardia's peer group compensation policies or the director's overall compensation package, a direct comparison to specific comparable companies or projects is not feasible from this filing alone. However, the structure of the grant is consistent with general industry practices for aligning director incentives.

Related Party Transactions

• The grant of stock options to Simon H. Stertzer, a Director of BioCardia, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's long-term interests with shareholder value, potentially leading to more focused decision-making for company growth.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted options will vest on December 8, 2026, subject to the director's continued service.

Key Dates

Keywords

BioCardia, BCDA, stock option, director, insider transaction, equity grant, executive compensation, Form 4